Biogen (BIIB) Approves $5B Stock Buyback Program

Biogen (NASDAQ: BIIB) announced that its Board of Directors authorized a program to repurchase up to $5 billion of the Company’s common stock. Biogen currently expects that purchases will be executed over the next three years. This share repurchase program is in addition to the approximately 1.3 million shares remaining under Biogen's February 2011 share repurchase program, which has been used principally to offset common stock issuances under the Company's share-based compensation plans.

You May Also Be Interested In

• Biogen expects $164M R&D charge to hit Q2 2026 earnings
• Nexa Resources confirms talks with Boliden over potential stake deal
• Cosmos Health buyback reaches 3.42M shares at ~$650,000 spent